Mary R.Waller

Associate

Chicago + 1.312.269.1566

Mary Waller represents health care and life sciences companies on a variety of complex regulatory and compliance issues, including for M&A transactions and health care fraud and abuse litigation. She has represented hospitals, health systems, physician groups, pharmaceutical and medical device manufacturers, and established and emerging digital health companies.

Mary has advised clients on regulatory and compliance issues, including direct-to-consumer telemedicine, licensure, patient consent, remote supervision, e-prescribing, and health information privacy and security compliance under the Health Insurance Portability and Accountability Act (HIPAA). She has supported clients engaged in M&A and other strategic transactions, including home health and physician practice acquisitions and private equity investments, and has participated in structuring various management service agreements and other arrangements to provide professional, management, or administrative services. Her experience also includes defending health care clients in investigations and litigation relating to the False Claims Act, the federal Anti-Kickback Statute, and the Stark Law brought by federal agencies and qui tam whistleblowers.

On the life sciences side, Mary has provided regulatory advice on issues associated with clinical research and the regulation of drugs and devices by the Food and Drug Administration (FDA). She also provides support to clients engaged in life sciences M&A and other transactions, including due diligence.

Mary sits on the Steering Committee for the Fellowships at Auschwitz for the Study of Professional Ethics and is a member of the American Health Lawyers Association and the Illinois Association of Healthcare Attorneys. She maintains an active pro bono practice, including education advocacy and asylum cases.

Experience

  • Integrated Medical Professionals sold to Lee Equity PartnersJones Day advised Integrated Medical Professionals, PLLC, a multi-specialty physician group specializing in urology, radiation oncology, and pathology, in its acquisition by Lee Equity Partners.
  • Digital health company expands telehealth programming in response to the COVID-19 public health crisisJones Day represented a digital health company in the expansion of their telehealth programming in response to the COVID-19 public health crisis.
  • Concord Health Partners participates in $25 million investment in Pieces TechnologiesJones Day represented Concord Health Partners LLC in connection with their investment in Pieces Technologies, a healthcare artificial intelligence and technology company that connects health systems and the community to address clinical and social determinants of health.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • OGE Energy acquires 146 MW combined cycle natural gas-fired power generation facilityJones Day advised Oklahoma Gas and Electric Company, a subsidiary of OGE Energy Corp., in the purchase of a 146 MW combined cycle natural gas-fired power generation facility from Oklahoma Cogeneration, LLC in Oklahoma City, and subsequently renamed it Frontier Power Plant.
  • Hill-Rom sells surgical consumable products to Audax Private Equity for $170 millionJones Day advised Hill-Rom Holdings, Inc. (NYSE: HRC), which recently rebranded as Hillrom, in its $170 million sale of certain surgical consumable products and related assets to an affiliate of Audax Private Equity.
  • OGE Energy acquires 360 MW coal-fired generation facilityJones Day advised Oklahoma Gas and Electric Company, a subsidiary of OGE Energy Corp., in the purchase of a 360 MW coal-fired generation facility and associated equipment from AES Shady Point, LLC, now known as River Valley Power Plant.
  • Nutrien prepares for engineering stack testsJones Day is assisting Nutrien Ltd. in evaluating possible ramifications of engineering stack tests of air emissions conducted prior to official compliance stack tests.
  • Nutrien prepares for inspection by Department of Homeland SecurityJones Day advised Nutrien Ltd. on various issues under Chemical Facility Anti-Terrorism Standards (CFATS) including preparation for an inspection by Department of Homeland Security (DHS).
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.